Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 24;9(5):428. doi: 10.3390/vaccines9050428

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Results of the Interferon-γ ELISpot after the second vaccination. (A) PBMCs were assayed by ex vivo interferon-γ ELISpot. Wells showing spot counts from post-vaccination PBMC samples obtained from blood drawn 19 days after the second vaccination. The specified peptide pools, consisting of several of the vaccinated peptides, were either vaccinated before (boost; second vac) or vaccinated for the first time (after first vaccination); tests were performed in triplicates. The negative control (- ctrl.—DMSO and water) was tested in six replicate wells and the positive control (+ ctrl.—phytohemagglutinin) in duplicate wells. The images representing the ELISpot wells were rearranged for this illustration. (B) PBMCs were assayed by interferon-γ ELISpot (100.000 cells/well), after 12 days of in vitro expansion in the presence of the relevant peptides (in vitro stimulation; IVS). PBMCs were isolated from blood drawn 5 days (left side) or 12 days (right side) after the second vaccination; peptides were either vaccinated before (boost; second vaccination) or newly vaccinated for the first time (after first vac), as indicated by the column number. Figure was designed with BioRender.